Powered by
ANN ARBOR—Esperion Therapeutics Inc., the Ann Arbor developer of novel cholesterol-fighting drugs, announced preliminary financial results and a new licensing agreement with Pittsford, N.Y.-based drug developer Serometrix. “As a result …
ANN ARBOR–Officials at Esperion Therapeutics Inc. (Nasdaq: ESPR) announced record revenue in the second quarter ended June 30, as its cholesterol-fighting drugs Nexletol and Nexlizet have been approved for use …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) reported a loss of $78.2 million or $2.84 a share in the first quarter of 2020, vs. net income of $87.4 million or $3.07 a …
ANN ARBOR—Esperion Therapeutics Inc. announced a collaboration agreement with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of Nexletol and Nexlizet tablets in Japan. Both medicines were recently approved …
ANN ARBOR—The European Commission has approved the sale of new cholesterol-lowering drugs from Ann Arbor-based Esperion Therapeutics Inc. (Nasdaq: ESPR). Approved were Nilemdo, a tablet containing the new drug bempedoic …
ANN ARBOR—After years of development, Nexletol, the new cholesterol-reducer from Ann Arbor’s Esperion Therapeutics Inc., is now on the market and available in pharmacies in the United States. Nexletol uses …
ANN ARBOR—The Ann Arbor cholesterol-lowering drug developer Esperino Therapeutics Inc. (NASDAQ: ESPR) announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 …
ANN ARBOR—Esperion Therapeutics Inc. (Nasdaq: ESPR) announced U.S. Food and Drug Administration approval of Nexlizet, a combination tablet of Esperion’s new non-statin cholesterol reducing drug bempedoic acid and an earlier …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ:ESPR) announced that the U.S. Food and Drug Administration (FDA) approved Nexletol (bempedoic acid) tablet, an oral, once-daily, non-statin cholesterol-lowering medicine. Nexletol is indicated as an …
ANN ARBOR—Esperion Therapeutics Inc. (NASDAQ: ESPR), the Ann Arbor pharma startup developing a new class of cholesterol-fighting drugs, announced positive top-line results from a Phase 2 clinical study of its combination …